Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure
New England Journal of Medicine1993Vol. 329(3), pp. 149–155
Citations Over TimeTop 1% of 1993 papers
Arthur M. Feldman, Michael R. Bristow, William W. Parmley, Peter E. Carson, Carl J. Pepine, Edward M. Gilbert, John E. Strobeck, G Hendrix, Eric R. Powers, Raymond P. Bain, B.G. White
Abstract
Six months of therapy with 60 mg of vesnarinone per day resulted in lower morbidity and mortality and improved the quality of life of patients with congestive heart failure. However, a higher dose of vesnarinone (120 mg per day) increased mortality, suggesting that this drug has a narrow therapeutic range; the long-term effects of vesnarinone are unknown.
Related Papers
- → Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure(2002)51 cited
- → Update on digoxin and other oral positive inotropic agents for chronic heart failure(1997)19 cited
- → Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy(1989)14 cited
- → Digitalis and other positive catecholamine-like inotropic agents in the management of congestive heart failure(1986)8 cited
- → Digitalis: Is It Useful in Congestive Heart Failure in Patients in Normal Sinus Rhythm?(1987)5 cited